{"protocolSection": {"identificationModule": {"nctId": "NCT00765674", "orgStudyIdInfo": {"id": "CSAH100A2302"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension", "officialTitle": "An 8 Week, Double-blind, Randomized, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate to Severe Hypertension"}, "statusModule": {"statusVerifiedDate": "2011-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-09"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-10-02", "studyFirstSubmitQcDate": "2008-10-02", "studyFirstPostDateStruct": {"date": "2008-10-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-01-12", "resultsFirstSubmitQcDate": "2011-04-15", "resultsFirstPostDateStruct": {"date": "2011-05-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-04-15", "lastUpdatePostDateStruct": {"date": "2011-05-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["aliskiren", "antihypertensive", "hypertension", "renin inhibitor", "moderate-severe hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1191, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren / amlodipine", "type": "EXPERIMENTAL", "description": "Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.", "interventionNames": ["Drug: Aliskiren", "Drug: Amlodipine", "Drug: Placebo"]}, {"label": "Aliskiren / hydrochlorothiazide", "type": "EXPERIMENTAL", "description": "Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.", "interventionNames": ["Drug: Aliskiren", "Drug: Hydrochlorothiazide (HCTZ)", "Drug: Placebo"]}, {"label": "Amlodipine / hydrochlorothiazide", "type": "EXPERIMENTAL", "description": "Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.", "interventionNames": ["Drug: Amlodipine", "Drug: Hydrochlorothiazide (HCTZ)", "Drug: Placebo"]}, {"label": "Aliskiren / amlodipine / hydrochlorothiazide", "type": "EXPERIMENTAL", "description": "Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.", "interventionNames": ["Drug: Aliskiren", "Drug: Amlodipine", "Drug: Hydrochlorothiazide (HCTZ)", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren", "description": "150 and 300 mg tablets", "armGroupLabels": ["Aliskiren / amlodipine", "Aliskiren / amlodipine / hydrochlorothiazide", "Aliskiren / hydrochlorothiazide"]}, {"type": "DRUG", "name": "Amlodipine", "description": "5 and 10 mg capsules", "armGroupLabels": ["Aliskiren / amlodipine", "Aliskiren / amlodipine / hydrochlorothiazide", "Amlodipine / hydrochlorothiazide"]}, {"type": "DRUG", "name": "Hydrochlorothiazide (HCTZ)", "description": "12.5 and 25 mg capsules", "armGroupLabels": ["Aliskiren / amlodipine / hydrochlorothiazide", "Aliskiren / hydrochlorothiazide", "Amlodipine / hydrochlorothiazide"]}, {"type": "DRUG", "name": "Placebo", "description": "tablet", "armGroupLabels": ["Aliskiren / amlodipine", "Aliskiren / amlodipine / hydrochlorothiazide", "Aliskiren / hydrochlorothiazide", "Amlodipine / hydrochlorothiazide"]}, {"type": "DRUG", "name": "Placebo", "description": "capsules", "armGroupLabels": ["Aliskiren / amlodipine", "Aliskiren / hydrochlorothiazide"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)", "description": "Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.", "timeFrame": "Baseline to end of study (Week 8)"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)", "description": "Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Percentage of Patients Achieving Blood Pressure Control at the End of the Study (Week 8)", "description": "Blood pressure control was defined as a msSBP/msDBP \\< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated.", "timeFrame": "End of study (Week 8)"}, {"measure": "Change in Mean 24-hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study (Week 8)", "description": "Twenty-four hour ambulatory blood pressure monitoring (ABPM) was performed in a subset of patients twice during the study, once at baseline and again at Week 8. The ABPM device was placed on the non-dominant arm between 7:00 and 10:00 am and verification readings obtained. If they were successful, the investigator initiated the 24 hour reading and instructed the patient regarding ABPM procedures. On the next day, the ABPM device was removed if it had been worn for a minimum of 24 hours. The ABPM data were downloaded and evaluated on site.", "timeFrame": "Baseline to end of study (Week 8)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female\n* 18 years of age or older\n* msDBP and msSBP requirements:\n\n  * 3A:\n\n    * Diagnosis of moderate to severe hypertension (msSBP \u2265 160 mmHg and \\< 200 mmHg, and/or msDBP \u2265 100 mmHg and \\< 120 mmHg) at Visits 4, 5 or 6 (Qualifying BP visit)\n    * In addition, at the visit immediately prior to the above qualifying visit, patients were also to have msSBP \u2265 145 mmHg and \\< 200 mmHg and msDBP \u2265 95 mmHg and \\< 120 mmHg) at Visits 3, 5 or 5.\n    * Patients had to meet the above two sets of requirements at subsequent adjacent visits, i.e. either Visits 3 and 4, Visits 4 and 5, or Visits 5 and 6.\n  * OR\n  * 3B:\n\n    * msSBP \u2265 180 mmHg and \\< 200 mmHg with msDBP \u2265 95 mmHg and \\< 120 mmHg, or msDBP \u2265 110 mmHg and \\< 120 mmHg with msSBP \u2265 150 mmHg and \\< 200 mmHg after at least one week of treatment with placebo (Visit 3 and on).\n\nExclusion Criteria:\n\n* Continued use of anti-hypertensive medicines or use of 4 or more hypertensive medicines at study start\n* Patients with an msSBP \u2265 200 mmHg or msDBP \u2265 120 mmHg at any time during the placebo run-in period were to be discontinued from the study.\n* Extremely elevated (defined) blood pressure at any point during the study\n* Pregnant or lactating women\n* Pre-menopausal women not taking accepted form of birth control\n* History or evidence of secondary form of hypertension\n* History of cardiovascular conditions\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Investigative Site", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Investigative Site", "city": "Sydney", "country": "Australia", "geoPoint": {"lat": -33.86785, "lon": 151.20732}}, {"facility": "Investigative Site", "city": "Ottawa", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Investigative Site", "city": "Copenhagen", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Investigative Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Investigative Site", "city": "Jerusalem", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Investigative Site", "city": "Rome", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Investigative Site", "city": "Riga", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Investigative Site", "city": "Vilnius", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Investigative Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Investigative Site", "city": "Stockholm", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Investigative Site", "city": "Ankara", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "In the single-blind period, 1909 patients were enrolled, 1189 completed, and 720 discontinued. Of the 1191 randomized patients, 2 patients were randomized by error and discontinued in the single-blind period without taking double-blind medication.", "groups": [{"id": "FG000", "title": "Aliskiren / Amlodipine", "description": "Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."}, {"id": "FG001", "title": "Aliskiren / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."}, {"id": "FG002", "title": "Amlodipine / Hydrochlorothiazide", "description": "Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"}, {"id": "FG003", "title": "Aliskiren / Amlodipine / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "287"}, {"groupId": "FG001", "comment": "1 patient was randomized in error and discontinued without taking any double-blind study medication.", "numSubjects": "298"}, {"groupId": "FG002", "numSubjects": "296"}, {"groupId": "FG003", "comment": "1 patient was randomized in error and discontinued without taking any double-blind study medication.", "numSubjects": "310"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "266"}, {"groupId": "FG001", "numSubjects": "276"}, {"groupId": "FG002", "numSubjects": "279"}, {"groupId": "FG003", "numSubjects": "285"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "17"}, {"groupId": "FG003", "numSubjects": "25"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "Abnormal Laboratory Value(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Abnormal Test Procedure Result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Randomized in Error - No Study Drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren / Amlodipine", "description": "Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."}, {"id": "BG001", "title": "Aliskiren / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."}, {"id": "BG002", "title": "Amlodipine / Hydrochlorothiazide", "description": "Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"}, {"id": "BG003", "title": "Aliskiren / Amlodipine / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "287"}, {"groupId": "BG001", "value": "298"}, {"groupId": "BG002", "value": "296"}, {"groupId": "BG003", "value": "310"}, {"groupId": "BG004", "value": "1191"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.4", "spread": "11.33"}, {"groupId": "BG001", "value": "55.5", "spread": "10.75"}, {"groupId": "BG002", "value": "55.1", "spread": "10.86"}, {"groupId": "BG003", "value": "55.4", "spread": "10.54"}, {"groupId": "BG004", "value": "55.1", "spread": "10.86"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "237"}, {"groupId": "BG001", "value": "242"}, {"groupId": "BG002", "value": "233"}, {"groupId": "BG003", "value": "251"}, {"groupId": "BG004", "value": "963"}]}]}, {"title": ">=65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "56"}, {"groupId": "BG002", "value": "63"}, {"groupId": "BG003", "value": "59"}, {"groupId": "BG004", "value": "228"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "115"}, {"groupId": "BG001", "value": "123"}, {"groupId": "BG002", "value": "110"}, {"groupId": "BG003", "value": "123"}, {"groupId": "BG004", "value": "471"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "172"}, {"groupId": "BG001", "value": "175"}, {"groupId": "BG002", "value": "186"}, {"groupId": "BG003", "value": "187"}, {"groupId": "BG004", "value": "720"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)", "description": "Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.", "populationDescription": "Full analysis set population: All randomized patients who had post-baseline efficacy measurements.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine", "description": "Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."}, {"id": "OG001", "title": "Aliskiren / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."}, {"id": "OG002", "title": "Amlodipine / Hydrochlorothiazide", "description": "Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"}, {"id": "OG003", "title": "Aliskiren / Amlodipine / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "282"}, {"groupId": "OG001", "value": "296"}, {"groupId": "OG002", "value": "295"}, {"groupId": "OG003", "value": "308"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-31.37", "spread": "0.90"}, {"groupId": "OG001", "value": "-27.99", "spread": "0.88"}, {"groupId": "OG002", "value": "-30.77", "spread": "0.88"}, {"groupId": "OG003", "value": "-37.92", "spread": "0.86"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)", "description": "Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.", "populationDescription": "Full analysis set population: All randomized patients who had post-baseline efficacy measurements.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine", "description": "Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."}, {"id": "OG001", "title": "Aliskiren / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."}, {"id": "OG002", "title": "Amlodipine / Hydrochlorothiazide", "description": "Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"}, {"id": "OG003", "title": "Aliskiren / Amlodipine / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "282"}, {"groupId": "OG001", "value": "296"}, {"groupId": "OG002", "value": "295"}, {"groupId": "OG003", "value": "308"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-18.03", "spread": "0.57"}, {"groupId": "OG001", "value": "-14.32", "spread": "0.55"}, {"groupId": "OG002", "value": "-17.03", "spread": "0.55"}, {"groupId": "OG003", "value": "-20.63", "spread": "0.54"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Blood Pressure Control at the End of the Study (Week 8)", "description": "Blood pressure control was defined as a msSBP/msDBP \\< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured at trough (24\u00b13 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated.", "populationDescription": "Full analysis set population: All randomized patients who had post-baseline efficacy measurements.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "End of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine", "description": "Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."}, {"id": "OG001", "title": "Aliskiren / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."}, {"id": "OG002", "title": "Amlodipine / Hydrochlorothiazide", "description": "Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"}, {"id": "OG003", "title": "Aliskiren / Amlodipine / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "283"}, {"groupId": "OG001", "value": "296"}, {"groupId": "OG002", "value": "295"}, {"groupId": "OG003", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41.3"}, {"groupId": "OG001", "value": "33.1"}, {"groupId": "OG002", "value": "39.0"}, {"groupId": "OG003", "value": "62.3"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean 24-hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study (Week 8)", "description": "Twenty-four hour ambulatory blood pressure monitoring (ABPM) was performed in a subset of patients twice during the study, once at baseline and again at Week 8. The ABPM device was placed on the non-dominant arm between 7:00 and 10:00 am and verification readings obtained. If they were successful, the investigator initiated the 24 hour reading and instructed the patient regarding ABPM procedures. On the next day, the ABPM device was removed if it had been worn for a minimum of 24 hours. The ABPM data were downloaded and evaluated on site.", "populationDescription": "Full analysis set population: All randomized patients who had post-baseline efficacy measurements.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine", "description": "Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."}, {"id": "OG001", "title": "Aliskiren / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."}, {"id": "OG002", "title": "Amlodipine / Hydrochlorothiazide", "description": "Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"}, {"id": "OG003", "title": "Aliskiren / Amlodipine / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "155"}, {"groupId": "OG002", "value": "136"}, {"groupId": "OG003", "value": "147"}]}], "classes": [{"title": "Systolic BP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.30", "spread": "0.52"}, {"groupId": "OG001", "value": "-16.27", "spread": "0.51"}, {"groupId": "OG002", "value": "-18.67", "spread": "0.53"}, {"groupId": "OG003", "value": "-25.29", "spread": "0.51"}]}]}, {"title": "Diastolic BP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.29", "spread": "0.36"}, {"groupId": "OG001", "value": "-9.57", "spread": "0.35"}, {"groupId": "OG002", "value": "-11.20", "spread": "0.37"}, {"groupId": "OG003", "value": "-15.90", "spread": "0.35"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "During the 8 week double blind treatment", "description": "Safety Set. All patients who received double-blind trial medication.", "eventGroups": [{"id": "EG000", "title": "Aliskiren / Amlodipine", "description": "Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.", "seriousNumAffected": 3, "seriousNumAtRisk": 287, "otherNumAffected": 32, "otherNumAtRisk": 287}, {"id": "EG001", "title": "Aliskiren / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.", "seriousNumAffected": 2, "seriousNumAtRisk": 297, "otherNumAffected": 17, "otherNumAtRisk": 297}, {"id": "EG002", "title": "Amlodipine / Hydrochlorothiazide", "description": "Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed", "seriousNumAffected": 2, "seriousNumAtRisk": 295, "otherNumAffected": 26, "otherNumAtRisk": 295}, {"id": "EG003", "title": "Aliskiren / Amlodipine / Hydrochlorothiazide", "description": "Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed", "seriousNumAffected": 6, "seriousNumAtRisk": 309, "otherNumAffected": 29, "otherNumAtRisk": 309}], "seriousEvents": [{"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 309}]}, {"term": "Arrhythmia supraventricular", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 309}]}, {"term": "Goitre", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 309}]}, {"term": "Hepatitis A", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 309}]}, {"term": "Tubo-ovarian abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 309}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 309}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 309}]}, {"term": "Ectopic pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 309}]}, {"term": "Psychosomatic disease", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 309}]}, {"term": "Stress urinary incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 309}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 309}]}, {"term": "Nasal septum deviation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 309}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 309}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 22, "numAtRisk": 309}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 287}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 297}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 295}, {"groupId": "EG003", "numAffected": 11, "numAtRisk": 309}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["South Africa"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}